ESUR Prostate MR Guidelines 2012

Overview

Journal Eur Radiol

Specialty Radiology

Date 2012 Feb 11

PMID 22322308

Citations 874

Authors

Jelle O Barentsz

Jonathan Richenberg

Richard Clements

Peter Choyke

Sadhna Verma

Geert Villeirs

Olivier Rouviere

Vibeke Logager

Jurgen J Futterer

Affiliations

Soon will be listed here.

Abstract

Unlabelled: The aim was to develop clinical guidelines for multi-parametric MRI of the prostate by a group of prostate MRI experts from the European Society of Urogenital Radiology (ESUR), based on literature evidence and consensus expert opinion. True evidence-based guidelines could not be formulated, but a compromise, reflected by "minimal" and "optimal" requirements has been made. The scope of these ESUR guidelines is to promulgate high quality MRI in acquisition and evaluation with the correct indications for prostate cancer across the whole of Europe and eventually outside Europe. The guidelines for the optimal technique and three protocols for "detection", "staging" and "node and bone" are presented. The use of endorectal coil vs. pelvic phased array coil and 1.5 vs. 3 T is discussed. Clinical indications and a PI-RADS classification for structured reporting are presented.

Key Points: This report provides guidelines for magnetic resonance imaging (MRI) in prostate cancer. Clinical indications, and minimal and optimal imaging acquisition protocols are provided. A structured reporting system (PI-RADS) is described.

Citing Articles

The presence of prostate MRI-visible lesions at follow-up biopsy as a risk factor for histopathological upgrading during active surveillance.

Viana P, Pinto P, Horvat N, Queiroz M, Cordeiro M, Coelho R Abdom Radiol (NY). 2025; .

PMID: 40072539 DOI: 10.1007/s00261-025-04871-6.

Additional findings in prostate MRI.

Poroes F, Karampa P, Sartoretti T, Najberg H, Froehlich J, Reischauer C Cancer Imaging. 2025; 25(1):29.

PMID: 40069885 PMC: 11895278. DOI: 10.1186/s40644-025-00846-4.

Validation of the Barcelona Magnetic Resonance Imaging Predictive Model for Significant Prostate Cancer Detection in Men Undergoing Mapping per 0.5 Mm-Core Targeted Biopsies of Suspicious Lesions and Perilesional Areas.

Paesano N, Catala V, Tcholakian L, Alomar X, Barranco M, Hernandez-Mancera J Cancers (Basel). 2025; 17(3).

PMID: 39941840 PMC: 11815984. DOI: 10.3390/cancers17030473.

Transition zone-based prostate-specific antigen density for differentiating clinically significant prostate cancer in PI-RADS score 3 lesions.

Jin Y, Chen F, Xu G, Wei C, Dong C Sci Rep. 2025; 15(1):3258.

PMID: 39863696 PMC: 11762996. DOI: 10.1038/s41598-025-87311-1.

Meeting Cancer Detection Benchmarks in MRI/Ultrasound Fusion Biopsy for Prostate Cancer: Insights from a Retrospective Analysis of Experienced Urologists.

Utzat F, Herrmann S, May M, Moersler J, Wolff I, Lermer J Cancers (Basel). 2025; 17(2).

PMID: 39858061 PMC: 11764349. DOI: 10.3390/cancers17020277.

References

Konety B, Bird V, Deorah S, Dahmoush L . Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol. 2005; 174(5):1785-8. DOI: 10.1097/01.ju.0000177470.84735.55. View

Oto A, Kayhan A, Jiang Y, Tretiakova M, Yang C, Antic T . Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology. 2010; 257(3):715-23. PMC: 6939960. DOI: 10.1148/radiol.10100021. View

Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C . Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol. 2011; 81(4):700-8. DOI: 10.1016/j.ejrad.2011.01.095. View

Coakley F, Teh H, Qayyum A, Swanson M, Lu Y, Roach 3rd M . Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology. 2004; 233(2):441-8. DOI: 10.1148/radiol.2332032086. View

Beyersdorff D, Taupitz M, Winkelmann B, Fischer T, Lenk S, Loening S . Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology. 2002; 224(3):701-6. DOI: 10.1148/radiol.2243011553. View

Klotz L . Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol. 2004; 47(1):16-21. DOI: 10.1016/j.eururo.2004.09.010. View

Shukla-Dave A, Hricak H, Ishill N, Moskowitz C, Drobnjak M, Reuter V . Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles. Clin Cancer Res. 2009; 15(11):3842-9. PMC: 2811524. DOI: 10.1158/1078-0432.CCR-08-2453. View

Lim H, Kim J, Kim K, Cho K . Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection--a multireader study. Radiology. 2008; 250(1):145-51. DOI: 10.1148/radiol.2501080207. View

Parkin D, Bray F, Devesa S . Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001; 37 Suppl 8:S4-66. DOI: 10.1016/s0959-8049(01)00267-2. View

10.

Collins D, Padhani A . Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag. 2004; 23(5):65-83. DOI: 10.1109/memb.2004.1360410. View

11.

Cornfeld D, Weinreb J . MR imaging of the prostate: 1.5T versus 3T. Magn Reson Imaging Clin N Am. 2007; 15(3):433-48, viii. DOI: 10.1016/j.mric.2007.06.004. View

12.

Itou Y, Nakanishi K, Narumi Y, Nishizawa Y, Tsukuma H . Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer?. J Magn Reson Imaging. 2010; 33(1):167-72. DOI: 10.1002/jmri.22317. View

13.

Testa C, Schiavina R, Lodi R, Salizzoni E, Corti B, Farsad M . Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology. 2007; 244(3):797-806. DOI: 10.1148/radiol.2443061063. View

14.

Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M . Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol. 2008; 54(3):589-600. DOI: 10.1016/j.eururo.2007.12.034. View

15.

Franiel T, Stephan C, Erbersdobler A, Dietz E, Maxeiner A, Hell N . Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning. Radiology. 2011; 259(1):162-72. DOI: 10.1148/radiol.10101251. View

16.

Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K . Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging. 2010; 31(3):625-31. DOI: 10.1002/jmri.22075. View

17.

Turkbey B, Shah V, Pang Y, Bernardo M, Xu S, Kruecker J . Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?. Radiology. 2010; 258(2):488-95. PMC: 3029887. DOI: 10.1148/radiol.10100667. View

18.

Wang L, Mazaheri Y, Zhang J, Ishill N, Kuroiwa K, Hricak H . Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology. 2007; 246(1):168-76. DOI: 10.1148/radiol.2461070057. View

19.

Mueller-Lisse U, Mueller-Lisse U, Scheidler J, Klein G, Reiser M . Reproducibility of image interpretation in MRI of the prostate: application of the sextant framework by two different radiologists. Eur Radiol. 2005; 15(9):1826-33. DOI: 10.1007/s00330-005-2695-z. View

20.

Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Lisi D, Osimani M . Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer. Cancer Invest. 2010; 28(4):424-32. DOI: 10.3109/07357900903287048. View